Taxus Set To Dominate? “Not So Fast,” Physicians Argue At Cordis ACC Event
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis will emphasize long-term data for its Cypher drug-eluting stent to counter the hype surrounding Boston Scientific's launch of Taxus